123 related articles for article (PubMed ID: 29452992)
1. Activity of ceftobiprole against Staphylococcus spec. isolates derived from foreign body associated infections.
Hischebeth GTR; Gravius S; Molitor E; Kohlhof H; Hoerauf A; Hilgers C; Randau TM
Diagn Microbiol Infect Dis; 2018 Jun; 91(2):175-178. PubMed ID: 29452992
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections.
Hodille E; Delouere L; Bouveyron C; Meugnier H; Bes M; Tristan A; Laurent F; Vandenesch F; Lina G; Dumitrescu O
Med Mal Infect; 2017 Mar; 47(2):152-157. PubMed ID: 27856079
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013-2015.
Henriksen AS; Smart J; Hamed K
Eur J Clin Microbiol Infect Dis; 2018 Sep; 37(9):1653-1659. PubMed ID: 29876773
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ceftobiprole against coagulase-negative staphylococci isolated in the USA.
Srinivasan V; McGowan JE; McAllister S; Tenover FC
Int J Antimicrob Agents; 2008 Mar; 31(3):294-6. PubMed ID: 18180145
[No Abstract] [Full Text] [Related]
6. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection.
Rouse MS; Steckelberg JM; Patel R
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):363-5. PubMed ID: 17449212
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
8. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
9. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
Farrell DJ; Flamm RK; Sader HS; Jones RN
Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes.
von Eiff C; Friedrich AW; Becker K; Peters G
Antimicrob Agents Chemother; 2005 Oct; 49(10):4372-4. PubMed ID: 16189125
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
12. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
Bogdanovich T; Ednie LM; Shapiro S; Appelbaum PC
Antimicrob Agents Chemother; 2005 Oct; 49(10):4210-9. PubMed ID: 16189100
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of ceftaroline against staphylococci from prosthetic joint infection.
Park KH; Greenwood-Quaintance KE; Patel R
Diagn Microbiol Infect Dis; 2016 Feb; 84(2):141-3. PubMed ID: 26602948
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of tedizolid against staphylococci isolated from prosthetic joint infections.
Schmidt-Malan SM; Greenwood Quaintance KE; Karau MJ; Patel R
Diagn Microbiol Infect Dis; 2016 May; 85(1):77-9. PubMed ID: 26906190
[TBL] [Abstract][Full Text] [Related]
16. In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
Lascols C; Legrand P; Mérens A; Leclercq R; Muller-Serieys C; Drugeon HB; Kitzis MD; Reverdy ME; Roussel-Delvallez M; Moubareck C; Brémont S; Miara A; Gjoklaj M; Soussy CJ
Int J Antimicrob Agents; 2011 Mar; 37(3):235-9. PubMed ID: 21295447
[TBL] [Abstract][Full Text] [Related]
17. New insights in the pathogenesis of foreign body infections with coagulase negative staphylococci.
Vandecasteele SJ; Van Wijngaerden E; Van Eldere J; Peetermans WE
Acta Clin Belg; 2000; 55(3):148-53. PubMed ID: 10981322
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the in vitro activities of ceftobiprole and comparators in staphylococcal colony or microtitre plate biofilm assays.
Abbanat D; Shang W; Amsler K; Santoro C; Baum E; Crespo-Carbone S; Lynch AS
Int J Antimicrob Agents; 2014 Jan; 43(1):32-9. PubMed ID: 24252780
[TBL] [Abstract][Full Text] [Related]
19. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Vaudaux P; Gjinovci A; Bento M; Li D; Schrenzel J; Lew DP
Antimicrob Agents Chemother; 2005 Sep; 49(9):3789-93. PubMed ID: 16127054
[TBL] [Abstract][Full Text] [Related]
20. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study.
Rossolini GM; Dryden MS; Kozlov RS; Quintana A; Flamm RK; Läuffer JM; Lee E; Morrissey I; CLASS Study Group
J Antimicrob Chemother; 2011 Jan; 66(1):151-9. PubMed ID: 21051375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
